Remus Pharmaceuticals Limited (NSE:REMUS)

India flag India · Delayed Price · Currency is INR
683.50
-0.90 (-0.13%)
At close: Oct 13, 2025
-0.13%
Market Cap3.98B
Revenue (ttm)6.20B
Net Income (ttm)290.70M
Shares Out5.83M
EPS (ttm)49.34
PE Ratio13.85
Forward PEn/a
Dividend1.50 (0.22%)
Ex-Dividend DateSep 18, 2025
Volume700
Average Volume5,435
Open670.00
Previous Close684.40
Day's Range660.05 - 683.50
52-Week Range636.10 - 1,385.00
Beta0.21
RSI24.11
Earnings DateNov 10, 2025

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels,... [Read more]

Industry Drugs, Drug Proprietaries, and Druggists' Sundries
Founded 2015
Employees 68
Stock Exchange National Stock Exchange of India
Ticker Symbol REMUS
Full Company Profile

Financial Performance

In 2024, Remus Pharmaceuticals's revenue was 6.20 billion, an increase of 191.33% compared to the previous year's 2.13 billion. Earnings were 290.70 million, an increase of 41.67%.

Financial Statements

News

There is no news available yet.